Flu News Friday: The Latest in Influenza Vaccines

--

November 6, 2020

Colorized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID

1. Upcoming Nov 13 Webinar: The Role of the Bioeconomy in Ending this Pandemic and Preventing the Next One

Georgetown University’s Global Health Initiative and Center for Global Health Science & Security / November 13, 2020

2. New Technologies for Influenza Vaccines

Rockman et al., Microorganisms / November 6, 2020

3. Daniel Ellis Talks Protein-Based Nanoparticles and Influenza Vaccines

Science In Seattle / November 4, 2020

4. Asia Today: South Korea OKs single test for COVID-19 and flu

Associated Press / November 4, 2020

5. Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines

Jackman et al., Advanced Functional Materials / November 4, 2020

6. Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem

Jiang et al., PLOS ONE / November 2, 2020

7. Recommended vaccinations still matter

Maryellen Kennedy Duckett, National Geographic / October 30, 2020

8. Flu shot: Seqirus presents absolute efficacy data on cell-based quadrivalent influenza vaccine

Outbreak News Today / October 29, 2020

9. Influenza Vaccines toward Universality through Nanoplatforms and Given by Microneedle Patches

Tan et al., Viruses / October 24, 2020

10. Why and How Vaccines Work

Iwasaki & Omer, Cell / October 15, 2020

11. Brief: What Can the United States Do to Prevent Another Pandemic? Commit to Modernizing Influenza Vaccines

Center for Strategic & International Studies / October 14, 2020

Visit Influenzer.org to learn more about our journey to accelerate the development of a universal influenza vaccine. @TheInfluenzers

--

--

The Influenzer Initiative
The Influenzer Initiative

Written by The Influenzer Initiative

Engaging and informing expertise from across research disciplines and industry sectors to drive innovation towards universal influenza vaccine development.

No responses yet